Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04587323 · ClinicalTrials.gov registry record
VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 75
- Enrollment target
NCT04587323 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 75 participants.
The verdict
NCT04587323 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 75 participants
- Enrollment target
Study Summary
To assess blood levels of vasoactive mediators that may regulate pulmonary endothelial permeability and contribute to multi-organ injury in patients with COVID-19 disease and to correlate the levels of these mediators with disease outcomes such as ICU admission, length of ventilatory support, respiratory failure, kidney failure, heart failure, and death.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2020-05-22 |
| Est. Completion | 2025-10-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04587323
The ClinicalTrials.gov registry entry for NCT04587323 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04587323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04587323 about?
NCT04587323 is a clinical study titled "VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease". To assess blood levels of vasoactive mediators that may regulate pulmonary endothelial permeability and contribute to multi-organ injury in patients with COVID-19 disease and to correlate the levels of these mediators with disease outcomes such as ICU admission, length of ventilatory support, respir...
What is the current status of trial NCT04587323?
This trial is currently completed. The enrollment target is 75 participants. The study started on 2020-05-22. Estimated completion is 2025-10-06.
Who is sponsoring clinical trial NCT04587323?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.